What Does the 5 November 2026 Session Signal for EBOS Group (ASX:EBO), Sigma Healthcare (ASX:SIG), and AFT Pharmaceuticals (ASX:AFP)?

Sonal Goyal

05 November 2026 06:16 PM AEDT

What Does the 5 November 2026 Session Signal for EBOS Group (ASX:EBO), Sigma Healthcare (ASX:SIG), and AFT Pharmaceuticals (ASX:AFP)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• EBOS Group (ASX:EBO) closed at A$17.40, up 1.40%, after delivering FY26 results with Revenue growth of 9.9% to A$13.5 billion.

• Sigma Healthcare (ASX:SIG) closed at A$2.82, gaining 1.08%, as the company continues to progress its operations within Australia's pharmaceutical distribution market.

• AFT Pharmaceuticals (ASX:AFP) closed at A$3.59, up 2.28%, following its September quarter investor update highlighting double-digit revenue growth in H1 FY27.

The S&P/ASX 200 (XJO) closed at 9,065.10 on 5 November 2026, up 2.61% or 230.60 points, while the S&P/ASX 200 Health Care index (XHJ) advanced 3.64%, adding 1,240.30 points to close at 35,329.10. Overnight Wall Street gains following the Democrats' decisive midterm election victory provided support across global Equity markets. Healthcare distribution and pharmaceutical companies EBOS Group Ltd (ASX:EBO), Sigma Healthcare Ltd (ASX:SIG), and AFT Pharmaceuticals Ltd (ASX:AFP) each recorded gains, though their advances were more modest than some of the sector's higher-growth names.

EBOS Group — FY26 Revenue Growth Across Healthcare and Animal Care

EBOS Group Ltd (ASX:EBO), an Australasian marketer, wholesaler, and distributor of healthcare products and animal care products, closed at A$17.40, up 1.40%. The company reported its FY26 full-year results on 19 August 2026, delivering revenue growth of 9.9% to A$13.5 billion and underlying EBITDA growth of 5.0% to A$614 million.

EBOS operates across two primary segments: healthcare, which includes pharmaceutical distribution, hospital supplies, and consumer healthcare products; and animal care, which provides veterinary and pet care products across Australia and New Zealand. The FY26 result was supported by broad-based growth across the healthcare division, and the company noted that its Investment cycle was complete, positioning it for continued value creation. EBOS is one of the largest companies in the Australasian healthcare distribution sector by revenue.

Sigma Healthcare — Pharmaceutical Distribution Operations

Sigma Healthcare Ltd (ASX:SIG), one of Australia's leading pharmaceutical distribution and retail pharmacy support companies, closed at A$2.82, up 1.08%. Sigma distributes pharmaceutical and personal care products to community pharmacies, hospitals, and other healthcare facilities across Australia.

The company released a market update in October 2026, providing details on its operational progress and strategic direction. Sigma has been focused on improving its distribution operations and supporting its pharmacy network, including the Amcal and Discount Drug Stores brands. The company continues to navigate a competitive distribution landscape alongside EBOS and other industry participants.

AFT Pharmaceuticals — Double-Digit Revenue Growth in H1 FY27

AFT Pharmaceuticals Ltd (ASX:AFP), a New Zealand-based pharmaceutical company, closed at A$3.59, up 2.28%. The company released its September quarter investor update on 6 October 2026, reporting double-digit revenue growth in the first half of FY27 and detailing progress across its Research and Development programmes.

AFT develops and markets a portfolio of pharmaceutical and healthcare products, including its Maxigesic pain relief brand, which is licensed in more than 100 countries. The quarterly update also provided information on the company's R&D pipeline, including progress on its CORIS product launch, which was noted as being on target for H1 FY27. AFT's Business model combines proprietary product development with a licensing and distribution strategy that extends its reach across global markets.

Sector Context

The pharmaceutical distribution and healthcare products sector in Australasia is characterised by scale-driven economics, regulatory frameworks, and long-standing relationships with pharmacy networks and healthcare providers. EBOS and Sigma are the two primary pharmaceutical distribution companies operating in the region, while AFT represents a product-focused model with a growing international licensing footprint. The broader healthcare sector's 3.64% advance on 5 November 2026 provided a supportive backdrop, though the more modest gains for these distribution-focused names reflect their typically lower-beta Earnings profiles.

The Bigger Picture

EBOS, Sigma Healthcare, and AFT Pharmaceuticals each advanced on 5 November 2026, participating in the healthcare sector's broad rally. EBOS's FY26 result underscored its position as the largest healthcare distributor in the region, while Sigma continues its operational focus within a competitive market. AFT's quarterly update highlighted revenue momentum and pipeline progress. These three companies collectively represent the distribution and product Supply chain that underpins Australia and New Zealand's healthcare system.

FAQs

Q: What does EBOS Group do?

A: EBOS is an Australasian marketer, wholesaler, and distributor of healthcare products and animal care products, with FY26 revenue of A$13.5 billion.

Q: What pharmacy brands does Sigma Healthcare support?

A: Sigma supports pharmacy brands including Amcal and Discount Drug Stores, alongside providing pharmaceutical distribution services to pharmacies and hospitals.

Q: What is AFT Pharmaceuticals' main product?

A: AFT's primary product is Maxigesic, a pain relief brand licensed in more than 100 countries. The company also has an R&D pipeline including the CORIS product.

Q: How did these stocks compare to the broader healthcare sector on 5 November?

A: All three recorded gains but underperformed the XHJ's 3.64% advance, with AFP up 2.28%, EBO up 1.40%, and SIG up 1.08%, reflecting their lower-beta earnings profiles.

Q: What factors influence pharmaceutical distribution companies in Australia?

A: Key factors include pharmacy network relationships, regulatory frameworks including the Pharmaceutical Benefits Scheme, scale efficiencies, and competition between the primary distributors.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.